| Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer … SP Whitman, KJ Archer, L Feng, C Baldus, B Becknell, BD Carlson, ... Cancer research 61 (19), 7233-7239, 2001 | 821 | 2001 |
| MicroRNA expression in cytogenetically normal acute myeloid leukemia G Marcucci, MD Radmacher, K Maharry, K Mrózek, AS Ruppert, ... New England Journal of Medicine 358 (18), 1919-1928, 2008 | 539 | 2008 |
| Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2 … C Röllig, H Serve, A Hüttmann, R Noppeney, C Müller-Tidow, U Krug, ... The lancet oncology 16 (16), 1691-1699, 2015 | 446 | 2015 |
| Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk … G Marcucci, K Maharry, MD Radmacher, K Mrózek, T Vukosavljevic, ... Journal of clinical oncology 26 (31), 5078, 2008 | 377 | 2008 |
| FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal … SP Whitman, AS Ruppert, MD Radmacher, K Mrózek, P Paschka, ... Blood, The Journal of the American Society of Hematology 111 (3), 1552-1559, 2008 | 360 | 2008 |
| Wilms’ tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study P Paschka, G Marcucci, AS Ruppert, SP Whitman, K Mrózek, K Maharry, ... Journal of Clinical Oncology 26 (28), 4595, 2008 | 335 | 2008 |
| BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study CD Baldus, SM Tanner, AS Ruppert, SP Whitman, KJ Archer, G Marcucci, ... Blood 102 (5), 1613-1618, 2003 | 310 | 2003 |
| Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations M Neumann, S Heesch, C Schlee, S Schwartz, N Gökbuget, D Hoelzer, ... Blood, The Journal of the American Society of Hematology 121 (23), 4749-4752, 2013 | 309 | 2013 |
| Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study G Marcucci, CD Baldus, AS Ruppert, MD Radmacher, K Mrózek, ... J Clin Oncol 23 (36), 9234-9242, 2005 | 302 | 2005 |
| Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2 … U Platzbecker, JM Middeke, K Sockel, R Herbst, D Wolf, CD Baldus, ... The Lancet Oncology 19 (12), 1668-1679, 2018 | 286 | 2018 |
| Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial J Cortes, AE Perl, H Döhner, H Kantarjian, G Martinelli, T Kovacsovics, ... The Lancet Oncology 19 (7), 889-903, 2018 | 256 | 2018 |
| High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses SK Metzelder, T Schroeder, A Finck, S Scholl, M Fey, K Götze, YC Linn, ... Leukemia 26 (11), 2353-2359, 2012 | 256 | 2012 |
| High Expression Levels of the ETS-Related Gene, ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal … G Marcucci, K Maharry, SP Whitman, T Vukosavljevic, P Paschka, ... Journal of clinical oncology 25 (22), 3337-3343, 2007 | 244 | 2007 |
| High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal … C Langer, MD Radmacher, AS Ruppert, SP Whitman, P Paschka, ... Blood, The Journal of the American Society of Hematology 111 (11), 5371-5379, 2008 | 240 | 2008 |
| Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study S Schwind, K Maharry, MD Radmacher, K Mrózek, KB Holland, ... Journal of clinical oncology 28 (36), 5257, 2010 | 228 | 2010 |
| Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes CD Baldus, S Liyanarachchi, K Mrózek, H Auer, SM Tanner, M Guimond, ... Proceedings of the National Academy of Sciences 101 (11), 3915-3920, 2004 | 219 | 2004 |
| BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications CD Baldus, C Thiede, S Soucek, CD Bloomfield, E Thiel, G Ehninger J Clin Oncol 24 (5), 790-797, 2006 | 217 | 2006 |
| Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts O Blau, CD Baldus, WK Hofmann, G Thiel, F Nolte, T Burmeister, ... Blood, The Journal of the American Society of Hematology 118 (20), 5583-5592, 2011 | 213 | 2011 |
| Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia O Blau, WK Hofmann, CD Baldus, G Thiel, V Serbent, E Schümann, ... Experimental hematology 35 (2), 221-229, 2007 | 203 | 2007 |
| Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid … C Langer, G Marcucci, KB Holland, MD Radmacher, K Maharry, ... Journal of clinical oncology 27 (19), 3198, 2009 | 198 | 2009 |
